Patient–Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey

American Journal of Men's Health

Volumn 11, Issue 1, 2017, Pages 134-146

  Bhuyan, Soumitra S ^a   Chandak, Aastha ^b   Gupta, Niodita ^b   Isharwal, Sudhir ^b   LaGrange, Chad ^b   Mahmood, Asos ^a   Gentry, Dan ^a  

^a UNIVERSITY OF MEMPHIS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

general health and wellness; health communication; healthcare issues; prostate cancer; Prostate specific antigen (PSA) testing

Indexed keywords

EID: 85006427536     PISSN: 15579883     EISSN: 15579891     Source Type: Journal    
DOI: 10.1177/1557988315614082     Document Type: Article

References (59)

1. Andriole G. L., Crawford E. D., Grubb R. L., Buys S. S., Chia D., Church T. R... Prorok P. C., (2012). Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. Journal of the National Cancer Institute, 104, 125-132.
2. Austin O. J., (2012). Prostate-specific antigen prostate cancer screening: Answers to the critical questions. Annals of Long Term Care, 20, 16-21.
3. Carpenter W. R., Godley P. A., Clark J. A., Talcott J. A., Finnegan T., Mishel M... Mohler J. L., (2009). Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use. Cancer, 115, 5048-5059.
4. Carter H. B., Albertsen P. C., Barry M. J., Etzioni R., Freedland S. J., Greene K. L... Zietman A. L., (2013). Early detection of prostate cancer: AUA guideline. Journal of Urology, 190, 419-426.
5. Centers for Disease Control and Prevention. (2014). Prostate cancer. Retrieved from http://www.cdc.gov/cancer/prostate/
6. Chan E. C., Vernon S. W., Haynes M. C., O’Donnell F. T., Ahn C., (2003). Physician perspectives on the importance of facts men ought to know about prostate-specific antigen testing. Journal of General Internal Medicine, 18, 350-356.
7. Close D. R., Kristal A. R., Li S., Patterson R. E., White E., (1998). Associations of demographic and health-related characteristics with prostate cancer screening in Washington state. Cancer Epidemiology Biomarkers & Prevention, 7, 627-630.
8. Cook E. D., Nelson A. C., (2011). Prostate cancer screening. Current Oncology Reports, 13(1), 57-62.
9. Denis L., Joniau S., Bossi A., Baskin-Bey E., Fitzpatrick J. M., (2012). PCA: Prostate cancer, patient-centred approach or both? BJU International, 110, 16-22.
10. Duffy M. J., (2011). Prostate-specific antigen: Does the current evidence support its use in prostate cancer screening? Annals of Clinical Biochemistry, 48, 310-316.
11. Eisen S. A., Waterman B., Skinner C. S., Scherrer J. F., Romeis J. C., Bucholz K... True W. R., (1999). Sociodemographic and health status characteristics associated with prostate cancer screening in a national cohort of middle-aged male veterans. Urology, 53, 516-522.
12. Ettner S. L., (1999). The relationship between continuity of care and the health behaviors of patients: Does having a usual physician make a difference? Medical Care, 37, 547-555.
13. Etzioni R., Berry K. M., Legler J. M., Shaw P., (2002). Prostate-specific antigen testing in black and white men: An analysis of Medicare claims from 1991–1998. Urology, 59, 251-255.
14. Feng B., Srinivasan M., Hoffman J. R., Rainwater J. A., Griffin E., Dragojevic M... Wilkes M. S., (2013). Physician communication regarding prostate cancer screening: Analysis of unannounced standardized patient visits. Annals of Family Medicine, 11, 315-323.
15. Flood A. B., Wennberg J. E., Nease R. F., Jr. Fowler F. J., Jr. Ding J., Hynes L. M., Prostate Patient Outcomes Research Team. (1996). The importance of patient preference in the decision to screen for prostate cancer. Journal of General Internal Medicine, 11, 342-349.
16. Forbat L., Place M., Kelly D., Hubbard G., Boyd K., Howie K., Leung H. Y., (2013). A cohort study reporting clinical risk factors and individual risk perceptions of prostate cancer: Implications for PSA testing. BJU International, 111, 389-395.
17. Gomella L. G., Liu X. S., Trabulsi E. J., Kelly W. K., Myers R., Showalter T... Wender R., (2011). Screening for prostate cancer: The current evidence and guidelines controversy. Canadian Journal of Urology, 18, 5875-5883.
18. Guerra C. E., Jacobs S. E., Holmes J. H., Shea J. A., (2007). Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. Journal of General Internal Medicine, 22, 901-907.
19. Han P. K., Coates R. J., Uhler R. J., Breen N., (2006). Decision making in prostate-specific antigen screening: National Health Interview Survey, 2000. American Journal of Preventive Medicine, 30, 394-404.
20. Han P. K., Kobrin S., Breen N., Joseph D. A., Li J., Frosch D. L., Klabunde C. N., (2013). National evidence on the use of shared decision making in prostate-specific antigen screening. Annals of Family Medicine, 11, 306-314.
21. Hoffman R. M., (2011). Screening for prostate cancer. New England Journal of Medicine, 365, 2013-2019.
22. Hoffman R. M., Couper M. P., Zikmund-Fisher B. J., Levin C. A., McNaughton-Collins M., Helitzer D. L... Barry M. J., (2009). Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study). Archives of Internal Medicine, 169, 1611-1618.
23. Hoffman R. M., Helitzer D. L., (2007). Moving towards shared decision making in prostate cancer screening. Journal of General Internal Medicine, 22, 1056-1057.
24. Kocher R., Emanuel E. J., DeParle N. A. M., (2010). The Affordable Care Act and the future of clinical medicine: The opportunities and challenges. Annals of Internal Medicine, 153, 536-539.
25. Landrey A. R., Matlock D. D., Andrews L., Bronsert M., Denberg T., (2013). Shared decision making in prostate-specific antigen testing the effect of a mailed patient flyer prior to an annual exam. Journal of Primary Care & Community Health, 4, 67-74.
26. Lin K., Lipsitz R., Miller T., Janakiraman S., (2008). Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US Preventive Services Task Force. Annals of Internal Medicine, 149, 192-199.
27. Mayo Clinic. (n.d.). Tests and procedures: PSA test. Retrieved from http://www.mayoclinic.org/tests-procedures/psa-test/basics/risks/prc-20013324
28. McCormick K. A., Osman N. Y., Pomerantz M. M., (2010). Update on prostate cancer screening. Journal of Clinical Outcomes Management, 17, 470-479.
29. Merrill R. M., (2001). Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Preventive Medicine, 33, 646-652.
30. Moyer V. A., (2012). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 157, 120-134.
31. Mukherjee K., Segal R., (2015). Discussions with healthcare providers about prostate-specific antigen testing: Evidence from the Behavioral Risk Factor Surveillance System in the USA. Journal of Pharmaceutical Health Services Research, 6(1), 47-52.
32. Murray E., Pollack L., White M., Lo B., (2007). Clinical decision-making: Patients’ preferences and experiences. Patient Education and Counseling, 65, 189-196.
33. National Cancer Institute. (n.d.-a). Frequently asked questions about HINTS. Retrieved from http://hints.cancer.gov/faq.aspx
34. National Cancer Institute. (n.d.-b). Health Information National Trends Survey 4 (HINTS 4). Retrieved from http://hints.cancer.gov/
35. Noguez J. H., Fantz C. R., (2014). Pathology consultation on prostate-specific antigen testing. American Journal of Clinical Pathology, 142, 7-15.
36. Pataky R., Gulati R., Etzioni R., Black P., Chi K. N., Coldman A. J... Peacock S., (2014). Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International Journal of Cancer, 135, 939-947.
37. Patient Protection and Affordable Care Act, 42 U.S.C. § 18001 et seq. (2010).
38. Potosky A. L., Legler J., Albertsen P. C., Stanford J. L., Gilliland F. D., Hamilton A. S... Harlan L. C., (2000). Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the prostate cancer outcomes study. Journal of the National Cancer Institute, 92, 1582-1592.
39. Qaseem A., Barry M. J., Denberg T. D., Owens D. K., Shekelle P., (2013). Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Annals of Internal Medicine, 158, 761-769.
40. Quinn M., Babb P., (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality: Part I. International comparisons. BJU International, 90, 162-173.
41. Robinson J. G., Hodges E., Davison J., (2014). Prostate-specific antigen screening: A critical review of current research and guidelines. Journal of the American Association of Nurse Practitioners, 26, 574-581.
42. Rutten L. J. F., Meissner H. I., Breen N., Vernon S. W., Rimer B. K., (2005). Factors associated with men’s use of prostate-specific antigen screening: Evidence from Health Information National Trends Survey. Preventive Medicine, 40, 461-468.
43. Sandblom G., Varenhorst E., Rosell J., Löfman O., Carlsson P., (2011). Randomised prostate cancer screening trial: 20 year follow-up. BMJ, 342, d1539.
44. SAS Institute. (SAS Version 9.4) [Computer software]. Cary, NC.
45. Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V... Auvinen A, ERSPC Investigators. (2009). Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine, 360, 1320-1328.
46. Scosyrev E., Messing E. M., Mohile S., Golijanin D., Wu G., (2011). Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. International Brazilian Journal of Urology, 37, 797-798.
47. Shaw E. K., Scott J. G., Ferrante J. M., (2013). The influence of family ties on men’s prostate cancer screening, biopsy, and treatment decisions. American Journal of Men’s Health, 7, 461-471.
48. Siegel R., Ma J., Zou Z., Jemal A., (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.
49. Sirovich B. E., Schwartz L. M., Woloshin S., (2003). Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA Journal of the American medical Association, 289, 1414-1420.
50. Smith R. A., Cokkinides V., Brawley O. W., (2009). Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA: A Cancer Journal for Clinicians, 59, 27-41.
51. Steele C. B., Miller D. S., Maylahn C., Uhler R. J., Baker C. T., (2000). Knowledge, attitudes, and screening practices among older men regarding prostate cancer. American Journal of Public Health, 90, 1595-1600.
52. Taylor K. L., DiPlacido J., Redd W. H., Faccenda K., Greer L., Perlmutter A., (1999). Demographics, family histories, and psychological characteristics of prostate carcinoma screening participants. Cancer, 85, 1305-1312.
53. Volk R. J., Linder S. K., Kallen M. A., Galliher J. M., Spano M. S., Mullen P. D., Spann S. J., (2013). Primary care physicians’ use of an informed decision-making process for prostate cancer screening. Annals of Family Medicine, 11(1), 67-74.
54. Walter L. C., Fung K. Z., Kirby K. A., Shi Y., Espaldon R., O’Brien S... Hoffman R. M., (2013). Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Internal Medicine, 173, 866-873.
55. Wolf A. M., Nasser J. F., Wolf A. M., Schorling J. B., (1996). The impact of informed consent on patient interest in prostate-specific antigen screening. Archives of Internal Medicine, 156, 1333-1336.
56. Wolf A. M., Schorling J. B., (1998). Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 53, M195-M200.
57. Wolf A. M., Wender R. C., Etzioni R. B., Thompson I. M., D’Amico A. V., Volk R. J... Smith RA, ; American Cancer Society Prostate Cancer Advisory Committee. (2010). American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA: A Cancer Journal for Clinicians, 60, 70-98.
58. Woolf S. H., (1995). Screening for prostate cancer with prostate-specific antigen: An examination of the evidence. New England Journal of Medicine, 333, 1401-1405.
59. WWAMI RUCA Rural Health Research Center. (n.d.). Using RUCA data. Retrieved from http://depts.washington.edu/uwruca/ruca-uses.php